Company / Cash per Share
Rapport Therapeutics, Inc. Cash per Share History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$2.74
FY2024
5-year range
$2.74 / $46.60
FY2023-FY2024
Trend
-94.1%
vs FY2023
Sector context
#78 of 205
Health Care
What the data says
At $2.74, Rapport Therapeutics, Inc.'s cash per share ranks #78 of 205 in the Health Care sector.
Based on SEC 10-K filings.
2.74 in FY2024.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#78 of 205 in Health CareTop 38% of 205This company $2.74 Sector average $72.93
▼
-96.2% below sector average
Key checks
Key Insights
- In FY2024, cash per share decreased 94.1% year-over-year.
- Ranks #78 out of 205 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 13.36 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $2.74 | -94.1% |
| FY2023 | $46.60 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026